VX 950

From Wikipedia, the free encyclopedia

VX 950, also known as Telaprevir, is an experimental treatment for hepatitis C that has completed phase I trials.[1] It is a member of a class of antiviral drugs known as protease inhibitors.

[edit] References

  1. ^ Reesink HW, Zeuzem S, Weegink CJ, et al. (2006). "Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study". Gastroenterology 131: 997–1002. doi:10.1053/j.gastro.2006.07.013. 
Tablets  This pharmacology-related article is a stub. You can help Wikipedia by expanding it.